The global enzymatic DNA synthesis (EDS) market was valued at USD 292.9 million in 2024 and is projected to reach USD 2,444.7 million by 2033, expanding at a robust CAGR of 26.65% from 2025 to 2033. This remarkable growth trajectory is primarily driven by continuous technological advancements, the increasing demand for precision medicine, and the rising pace of research in synthetic biology. Furthermore, significant investments and funding in genetic research and biotechnology are enhancing the capabilities of laboratories and research organizations to adopt enzymatic DNA synthesis technologies. The market is witnessing widespread acceptance of EDS methods, as they offer a sustainable, efficient, and environmentally friendly alternative to conventional chemical DNA synthesis processes. The growing application of DNA synthesis across genomics, diagnostics, therapeutics, and vaccine development is expected to further propel market demand in the coming years.

The degree of innovation in the enzymatic DNA synthesis industry is moderate, reflecting a steady progression rather than a disruptive transformation. Although major technological breakthroughs such as improvements in enzyme engineering, nucleotide chemistry, and process automation have significantly enhanced the accuracy, yield, and scalability of DNA synthesis, innovation within the sector remains consistent and incremental. The primary focus among leading companies has been on refining enzyme efficiency and synthesis fidelity while simultaneously reducing costs and turnaround times. As a result, enzymatic DNA synthesis is increasingly becoming a preferred solution for high-throughput and on-demand applications in genomics, synthetic biology, and personalized medicine. Moreover, the integration of microfluidics, artificial intelligence, and chip-based synthesis technologies is expected to further elevate precision and throughput, setting the stage for future advancements.

The enzymatic DNA synthesis market is also characterized by a moderate level of merger and acquisition (M&A) activity, as both established players and emerging biotechnology firms pursue strategic alliances to strengthen their technological capabilities and expand their market reach. These collaborations and acquisitions allow companies to gain access to novel technologies, enter untapped regional markets, and achieve economies of scale in production. Strategic partnerships between biotech firms, pharmaceutical companies, and research institutions are fostering innovation by combining complementary expertise in enzymology, automation, and computational biology. This trend is expected to intensify over the forecast period, driving further competition while promoting the development of next-generation EDS platforms that can meet the increasing complexity of modern genetic research and biomanufacturing needs.

Key Market Trends & Insights:

• Regional Insights: North America held the largest market share of 49.83% in 2024, driven by strong investments in genetic research, a mature biotechnology sector, and the presence of key industry players. The U.S. market is expected to continue its dominance due to the expanding adoption of precision medicine and government support for synthetic biology initiatives.
• By Type: The oligonucleotide synthesis segment held the highest market share in 2024, supported by widespread use in PCR, diagnostics, and drug development. The gene synthesis segment is expected to register the fastest CAGR during the forecast period, propelled by the increasing need for long and complex DNA constructs for gene therapy and vaccine production.
• By Application: The synthetic biology segment accounted for the largest share of 36.55% in 2024, as DNA synthesis is foundational to designing and constructing biological systems. The vaccine development segment is projected to grow at a CAGR of 26.99%, reflecting the increasing reliance on EDS technologies for rapid and accurate vaccine prototyping.
• By End Use: The large biopharmaceutical companies segment dominated the market in 2024, driven by their high R&D expenditure and extensive adoption of enzymatic methods for drug and biologics development. Meanwhile, the contract research organizations (CROs) segment is anticipated to record the fastest growth, owing to increased outsourcing of DNA synthesis services by pharma and biotech firms to optimize operational efficiency.

Order a free sample PDF of the Enzymatic DNA Synthesis Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2024 Market Size: USD 292.9 Million
• 2033 Projected Market Size: USD 2,444.7 Million
• CAGR (2025-2033): 26.65%
• North America: Largest market in 2024
• Asia Pacific: Fastest growing market

Key Companies & Market Share Insights:

The global EDS market features a mix of established synthetic biology leaders and innovative emerging companies working toward improving DNA synthesis capabilities.

• Telesis Bio Inc. remains a frontrunner with its BioXp systems, which automate and accelerate gene synthesis using enzymatic methods. The company’s platforms have reduced the time and complexity involved in synthetic DNA production, allowing researchers to create custom genetic constructs with high precision.
• Twist Bioscience Corporation, known for its chemical DNA synthesis expertise, is diversifying into hybrid platforms that combine chemical and enzymatic techniques to enhance throughput and flexibility.
• GenScript Biotech Corp., a key player in gene synthesis services, is gradually integrating enzymatic synthesis methods to deliver faster turnaround times and improved sequence accuracy, aligning with the growing demand for high-quality DNA products.
• Several emerging innovators are reshaping the competitive landscape with next-generation synthesis technologies:
• Evonetix and Ansa Biotechnologies, Inc. are pioneering chip-based and sequence-perfect enzymatic synthesis solutions, respectively, enabling the creation of long and complex DNA fragments with unprecedented precision.
• Camena Bio is gaining traction through its proprietary DNA assembly platforms, targeting applications in synthetic biology and gene circuit design.
• Molecular Assemblies, in collaboration with Codexis, has developed Fully Enzymatic Synthesis technology, enabling the synthesis of long, accurate DNA strands suitable for diagnostics, therapeutics, and biomanufacturing applications.
• DNA Script, headquartered in France, is a leading contributor to decentralized DNA synthesis, offering benchtop enzymatic DNA printers that allow academic and pharmaceutical institutions to conduct on-demand gene synthesis.

In addition, companies such as Touchlight and Kern Systems are leveraging proprietary enzymatic processes to produce DNA for advanced applications, including therapeutics, vaccines, and data storage. Touchlight’s unique “doggybone” DNA format and Kern Systems’ high-fidelity synthesis platforms represent key innovations that expand the use cases of EDS beyond conventional gene synthesis. These firms are actively engaging in strategic collaborations, licensing agreements, and joint ventures with academic institutions and government bodies to accelerate commercialization and market penetration.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

In conclusion, the global enzymatic DNA synthesis (EDS) market is poised for rapid expansion, driven by advancements in biotechnology, growing applications in precision medicine, and the increasing adoption of sustainable DNA synthesis methods. The shift from chemical to enzymatic synthesis reflects a broader industry trend toward faster, more accurate, and environmentally friendly genetic engineering solutions. Continuous innovation, strategic collaborations, and investments in automation are enhancing efficiency and scalability, enabling broader commercial adoption across healthcare, research, and biomanufacturing sectors. As major players and emerging innovators push the boundaries of enzyme technology, the EDS market is set to play a pivotal role in shaping the future of genomics, synthetic biology, and therapeutic development.